Summary:
1. Therini Bio, Inc., a biotech company in Sacramento, CA, secured $39 million in Series A extension financing for their fibrin-targeting immunotherapies for neurodegenerative diseases.
2. The funding round included new investors Angelini Ventures and Apollo Health Ventures, bringing the total Series A funding to $75 million.
3. Therini Bio will use the funds to support Phase 1b trials for their lead candidate, THN391, aimed at treating Alzheimer’s Disease and Diabetic Macular Edema.
Revised Article:
Therini Bio, Inc. Raises $39M in Series A Extension Financing
Therini Bio, Inc., a clinical-stage biotech company based in Sacramento, CA, recently announced a significant milestone in their funding journey. The company, focused on developing innovative fibrin-targeting immunotherapies for neurodegenerative diseases, successfully raised $39 million in a Series A extension financing round.
This latest round of financing saw the entry of new investors, including Angelini Ventures and Apollo Health Ventures, alongside existing investors such as SV Health Investors’ Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures, and Foundation for a Better World. The additional funding has brought Therini Bio’s total Series A funding to an impressive $75 million.
Advancing Treatments for Neurodegenerative Diseases
Under the leadership of Tara Nickerson, Ph.D., Chief Executive Officer, Therini Bio is on a mission to target the underlying causes of neurodegeneration. The company’s research focuses on addressing vascular dysfunction driven by factors like aging, genetics, hypertension, and diabetes, which contribute to the accumulation of toxic fibrin deposits outside blood vessels. These deposits trigger chronic neuroinflammation, leading to neuronal damage and severe neurodegenerative diseases.
Therini Bio’s lead candidate, THN391, is a high-affinity humanized monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation without impacting coagulation pathways. Preclinical studies have shown promising results in preventing vascular and neuronal degeneration in diseases like Alzheimer’s Disease and retinal conditions.
Preparing for Phase 1b Trials
Following a successful Phase 1a trial where THN391 demonstrated good tolerability and safety profiles in healthy volunteers, Therini Bio is gearing up to initiate Phase 1b trials for evaluating the candidate in Alzheimer’s Disease and Diabetic Macular Edema patients. The financing secured will support these crucial trials, paving the way for potential advancements in the treatment of these debilitating conditions.
With a strong focus on innovation and a commitment to addressing the unmet needs in neurodegenerative diseases, Therini Bio is poised to make a significant impact in the field of biotechnology and healthcare.
Source: Therini Bio, Inc.
